Hantavirus Researchers Pursue Drug and Vaccine Solutions Following 2026 Cruise Ship Outbreak

A 2026 hantavirus outbreak linked to a cruise ship has accelerated research into treatments and vaccines for Andes virus, the only hantavirus capable of human-to-human transmission. Researchers have identified promising therapeutic approaches: tocilizumab, used for rheumatoid arthritis, showed potential in reducing fatal pulmonary inflammation (4 of 5 treated patients survived vs. 5 of 5 untreated controls who died, though the latter were sicker). Teams in Chile, Argentina, and the US are also developing monoclonal antibody therapies and vaccines; an Army-led vaccine candidate has generated antibodies in early human trials. However, funding remains constrained because hantavirus is rare and sporadic, making large clinical trials impractical and commercial markets uncertain. Scientists hope the outbreak's visibility will catalyze sustained investment to advance these candidates toward regulatory approval.